Journal of
eISSN: 2376-0060
Submit manuscript...
Editorial Volume 9 Issue 4
Differences in levels of plasma, salivary, and nasal antibody to SARS-CoV-2 (Covid-19) after Covid-19 vaccination and during natural infection
Attapon Cheepsattayakorn,1,2 
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Ruangrong Cheepsattayakorn,3 Porntep Siriwanarangsun1
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
1Faculty of Medicine, Western University, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand
Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand
Received: December 19, 2022 | Published: December 23, 2022
Citation: Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. Differences in levels of plasma, salivary, and nasal antibody to SARS-CoV-2 (Covid-19) after Covid-19 vaccination and during natural infection. J Lung Pulm Respir Res. 2022;9(4):100. DOI: 10.15406/jlprr.2022.09.00288
Editorial
Cellular or antibody responses is measured in the most studies of immunity to SARS-CoV-2 (COVID-19).1 Nevertheless, if ever SARS-CoV-2 (COVID-19) present in the plasma, the infectious virus is rarely infects the nasal and conjunctival mucosal surfaces.1 In COVID-19-infected-unvaccinated and unvaccinated-COVID-19-uninfected individuals, the levels of nasal and salivary anti-spike antibody correlated significantly with plasma antibody.1,2 The reported mean correlations for titers in plasma and saliva for IgG and IgA were moderate (p = 0.55; 95 % CI : 0.38-9.73) and weak (p = 0.28; 95 % CI : 0.12-0.44), respectively.2 A previous systematic review demonstrated that previous-COVID-19-infected-vaccinated individuals demonstrated boosting anti-spike antibody levels in the nose or saliva less than in plasma.1
In conclusion, potent immune response induced by COVID-19 mucosal vaccines at the sites of SARS-CoV-2 (COVID-19) infection is urgently needed. Persistent mucosal antibody may not indicate persistent increase of SARS-CoV-2 plasma antibody levels.
Acknowledgments
None.
Conflicts of interest
There are no conflicting interests declared by the authors.
References
- Cohen JI, Dropulic L, Wang K, et al. Comparison of levels of nasal, salivary, and plasma antibody to SARS-CoV-2 during natural infection and after vaccination. Clin Infect Dis.2022.
- Guerra ENS, De Castro VT, Dos Santos JA, et al. Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: a rapid systematic review. Front Immunol. 2022.
©2022 Cheepsattayakorn, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.
Citations
November is Lung Cancer Awareness Month, a vital opportunity for us to raise awareness about the dangers of lung cancer. Let’s unite to educate ourselves and others, and inspire proactive steps toward lung health. This year the motto of this event is “Stronger Together: United for Lung Cancer Awareness”. So for this occasion, the Journal of Lung, Pulmonary & Respiratory Research invites articles that emphasize the significance of lung protection. All the submissions received in the month of November will be offered with 40% discount on publication.